Impulse Dynamics Closes $60 Million Financing

NEWS

Funding to Accelerate Clinical and Product Development Pipelines, Commercialization of Optimizer Smart System for Heart Failure

MARLTON, N.J., January 12, 2021 — Impulse Dynamics, a company dedicated to helping healthcare providers improve the lives of people with heart failure, today announced the completion of a $60 million supplemental Series D crossover financing with new investors, anchored by CR-CCT Industry Pilot Fund together with Redmile Group and Perceptive Advisors. Proceeds of the financing will be used for general corporate purposes, including acceleration of clinical and product development activities along with continued U.S. commercialization of the Optimizer Smart, an FDA-approved implantable device for treating chronic heart failure that has been proven to strengthen the heart and help it beat more forcibly.

The transaction closed in late December. “We are extremely pleased to be adding these sophisticated investors to our robust existing group, all of whom recognize the significant potential of our breakthrough technologies for an immense group of patients with major unmet needs.” said Gerry Haines, CFO of Impulse Dynamics. “With our mature product development pipeline and two additional breakthrough designations, it is exciting to see the potential for cardiac contractility modulation therapy to play an even larger role in improving the lives of patients who continue to suffer with this debilitating disease. We look forward to accelerating key development activities, designed to serve new and larger groups of patients in need, in parallel with the continuing expansion of our commercial operations.”

Heart failure is a chronic and progressive condition affecting an estimated 26 million people worldwide, with nearly 6 million of those in the U.S. alone.^1,2 For people living with the disease, the heart is not able to pump forcibly enough to meet the body’s needs. Over time, this leads to symptoms including breathlessness and fatigue, making even simple, everyday activities challenging. For eligible patients, CCM^® therapy with the Optimizer^® Smart provides a new alternative to alleviate symptoms and improve quality of life, bringing hope to millions.

The Optimizer^® delivers CCM^® therapy, the company’s proprietary technology, to the heart through a device is similar in size to a pacemaker. It is implanted during a minimally invasive procedure while a patient is under light sedation and has been used to treat over 5,000 patients worldwide. It is currently available in the United States, Europe, China, Brazil, India and more than 40 other countries around the world.

CCM^® therapy is the first approach of its kind designed to improve contraction of the heart, allowing more oxygen-rich blood to reach the body.³ CCM^® therapy delivers precisely timed electrical pulses to the heart during the absolute refractory period of the beating cycle, just after the heart contracts. This breakthrough technology has the potential to improve the quality of life for patients who are no longer adequately responding to medications to manage their symptoms or slow the progression of their condition.³

About the Optimizer and CCM Therapy

CCM is the brand name for Cardiac Contractility Modulation, the non-excitatory electrical pulses delivered by the implantable Optimizer device to improve systolic contraction of the heart. The Optimizer Smart System was granted Breakthrough Device designation by the U.S. Food and Drug Administration, and it is the first and only CCM device approved in the U.S. CCM therapy sends unique electrical pulses to the heart cells during the absolute refractory period, which occurs just after the heart initiates contractions. In doing so, it strengthens and helps the heart contract more forcibly. Impulse Dynamics has completed numerous clinical studies, including several randomized controlled trials, the results of which have been published in over 80 articles appearing in leading medical journals. Studies have shown CCM therapy to sustainably improve 6-minute hall walk distance, quality of life and functional status among patients who are candidates for the device. The Optimizer Smart has been implanted in over 4,000 patients and is currently available in the U.S., Europe, China, Brazil, India and more than 40 other countries around the world.

About Impulse Dynamics

Impulse Dynamics, based in Marlton, N.J., is dedicated to helping healthcare providers improve the lives of people with heart failure by transforming how the condition is treated. The company has pioneered CCM^® therapy, which is delivered by the company’s Optimizer^® system, a breakthrough, FDA-approved treatment that is proven to improve the quality of life for heart failure patients.¹ CCM therapy is a safe and effective minimally invasive treatment option for many heart failure patients who otherwise have few effective options available to them.¹ To learn more visit www.impulse-dynamics.com, or follow the company on LinkedIn and Twitter.

Impulse Dynamics (USA), Inc.
50 Lake Center Executive Parkway, 401 Route 73 N, ‐ Building 50 Suite 100
Marlton, NJ 08053
Phone: (856) 642‐9933
www.impulse‐dynamics.com

INVESTOR CONTACT:

Gerry Haines, CFO
Impulse Dynamics
g.haines@impulse-dynamics.com

MEDIA CONTACT:

Rex Richmond
rex.richmond@impulse-dynamics.com
612-201-1540

References

1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494150/aa

2 Mozzafarian D, Benjamin EJ, Go AS, et al. on behalf of the American Heart Association Statistics Committee and
Stroke Statistics Subcommittee. Heart disease and stroke statistics—2016 update: a report from the American Heart
Association. Circulation. 2016; 133:e38-e360.

3 Abraham WT, Kuck KH, Goldsmith RL, et al. A randomized controlled trial to evaluate the safety and efficacy of
cardiac contractility modulation. JACC Heart Failure. 6(10), 874-883 (2018).